Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant mycobacterium tuberculosis clinical isolates;Çok i̇laca dl̇rençli̇ mycobacterium tuberculosis kli̇ni̇k i̇zolatlarina karşi li̇nezoli̇di̇n i̇zoni̇azjd ve ri̇fampi̇si̇n i̇le kombi̇ne etki̇si̇

Mikrobiyoloji Bulteni

Volumn 43, Issue 2, 2009, Pages 293-297

  Çoban, Ahmet Yilmaz ^a   Blgn, Kemal ^a   Uzun, Meltem ^b   Durupinar, Belma ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Combination; Linezolid; Multidrug resistant Mycobacterium tuberculosis

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; ISONIAZID; LINEZOLID; OXAZOLIDINONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG EFFECT; DRUG POTENTIATION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS;

ACETAMIDES; ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 67649560617     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fattorini L, Tan D, Lona E, et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob Agents Chemother 2003; 47: 360-2.
2. Shoen CM, De Stefano MS, Sklaney MR, et al. Short-course treatment regimen to identify potential antituberculous agent in a murine model of tuberculosis. J Antimicrob Chemother 2004; 53: 641-5.
3. Bozdogan B, Appelbaum PC. Oxazolidinones: activities, mode of action, and mechanisms of resistance. Int J Antimicrob Agents 2004; 23: 113-9.
4. Rodriguez JC, Ruiz M, Lopez M, et al. In vitro activity of moxifloxacin, levofloxacin, gatifoxacin and linezolid against Mycobacterium tuberculosis. Int) Antimicrob Agents 2002; 20: 464-7.
5. Alcala L, Ruiz-Serrano MJ, Turegano CP, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant first-line antituberculous drugs. Antimicrob Agents Chemother 2003; 47: 416-7.
6. Erturan Z, Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2005; 26: 78-80.
7. Tato M, de la Pedrosa EG, Canton R, et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 2006; 28: 75-8.
8. th ed. Lippincott Co. Philadelphia.
9. Leite CQF, Berette ALRZ, Anno IS, et al. Standardization of broth microdilution method for Mycobacterium tuberculosis. Mem Inst Oswaldo Cruz 2000; 95:127-9.
10. Coban AY, Birinci A, Ekinci B, et al. Drug susceptibility testing of Mycobacterium tuberculosis by the broth microdilution method with 7H9 broth. Mem Inst Oswaldo Cruz 2004; 99: 111-3.
11. Rüsch-Gerdes S, Pfyffer GE, Casal M, et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
12. Richter E, Rüsch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51: 1534-6.
13. Sood R, Rao M, Singhal S, et al. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int J Antimicrob Agents 2005; 25: 464-8.
14. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-5.
15. Diaz JCR, Ruiz M, Lopez M, et al. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2003; 21: 354-6.